Back to Feed
ClinicalTrials.gov|Clinical Trial
Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease
Mesoblast, Inc.
Abstract
Protocol 610 is enrolling subjects who successfully achieved clinical benefit (reduction in Crohn's Disease Activity Index (CDAI) of at least 100 points) in Protocol 603. Protocol 610 is evaluating the length of initial effect of PROCHYMAL® adult human mesenchymal stem cells and the ability of these cells to successfully re-induce clinical benefit. Phase: PHASE3 Status: COMPLETED Conditions: Crohn's Disease Interventions: Placebo; PROCHYMAL adult human mesenchymal stem cells
Keywords
Crohn's Disease